Phase 2 N=36 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,004 A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Urinary Tract Cancer
Primary: Percentage of Participants With Adverse Events (AEs) — 900 Participants
Phase 3 N=1,213 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm…
Phase 2 N=310 A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
Bladder Cancer
Primary: Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF)…
Phase 2 N=36 Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma · Bladder Cancer
Primary: Count of Participants With Response Measured by RECIST 1.1 — 16 Participants
Phase 2 N=49 Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants
Phase 3 N=931 A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Bladder Cancer
Primary: Overall Survival (OS) — 10.6; 11.1; 8.2; 8.9 Months — p=0.4134
Phase 2 N=119 A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
Bladder Cancer
Primary: Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF)…
Phase 2 N=36 Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
Urothelial Carcinoma
Primary: Percentage of Patients That Respond to Treatment — 18 Participants
Phase 2 N=43 CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Bladder Cancer
Primary: Objective Response Rate (ORR) — 1; 2 Participants
Phase 2 N=69 Cabozantinib for Advanced Urothelial Cancer
Urothelial Carcinoma · Urethral Neoplasms · Urinary Bladder Neoplasms
Primary: Percentage of Participants With Overall Response — 19.1; NA; NA percentage of participants
Phase 3 N=542 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Urothelial Cancer
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - All Participants — 3.3; 2.1 Months — p=0.41648
Phase 3 N=700 A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Urothelial Cancer
Primary: Overall Survival (OS) — 21.4; 14.3 months — p=0.0005
Phase 2 N=113 Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
Locally Advanced or Metastatic Urothelial Bladder Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC) — 24.0 Percentage of participants — p=< 0.0001
Phase 2 N=26 Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
Urothelial Carcinoma
Primary: Objective Response Rate — 8.3 Percentage of participants
Phase 2 N=38 Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)
Urologic Neoplasms
Primary: Best Overall Tumor Response — 2; 13; 13; 1 participants
Phase 2 N=78 Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
Metastatic Urothelial Carcinoma
Primary: Number of Participants With Overall Response — 9; 8 Participants
Phase 2 N=50 Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
Neoplasms
Primary: Objective Tumour Response According to RECIST Criteria — 14.0 Percentage of participants
Phase 2 N=374 Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
Urothelial Cancer
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants — 28.9 Percentage of participants
Phase 3 N=84 Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
UC (Urothelial Cancer)
Primary: Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo — 21.4; 9.5 percentage of participants
Phase 2 N=47 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
Advanced Bladder Urothelial Carcinoma · Advanced Ureter Urothelial Carcinoma · Metastatic Bladder Urothelial Carcinoma
Primary: Objective Response Rate (ORR) — 3; 4; 0; 2 Participants — p=0.428
Phase 2 N=14 Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Urothelial Carcinoma
Primary: Overall Response Rate — 11 Participants
Phase 2 N=188 A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
Urinary Bladder Neoplasm · Neoplasm Metastasis
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Per Blinded Independent Central Review (BICR) in Patients Whose Tumors Have…
Phase 2 N=219 A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Carcinoma, Transitional Cell · Urinary Bladder Neoplasms · Urologic Neoplasms
Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) — 44; 51.7 Percentage of Participants
Phase 2 N=66 Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma
Locally Advanced or Metastatic Urothelial Carcinoma
Primary: Overall Response Rate (ORR) — 48.5 Percentage of patients with response
Phase 2 N=19 Pazopanib in Treating Patients With Metastatic Urothelial Cancer
Distal Urethral Cancer · Proximal Urethral Cancer · Recurrent Bladder Cancer
Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants
N/A N=106 A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
Urothelial Cancer
Primary: Real-World Overall Survival — 16.8 months
Phase 2 N=19 Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Metastatic Transitional Cell Carcinoma of the Urothelium
Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS
Phase 2 N=13 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Urothelial Carcinoma · Ureteral Neoplasms · Ureter Cancer
Primary: Progression Free Survival — 1.9 Months
Phase 2 N=27 Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Transitional Cell Carcinoma
Primary: Overall Response Rate — 3; 6; 9; 7 Participants